Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer

British Journal of Cancer

Volumn 89, Issue 5, 2003, Pages 795-802

  Kiura, K ^a   Ueoka, H ^a   Segawa, Y ^f   Tabata, M ^a   Kamei, H ^c   Takigawa, N ^a   Hiraki, S ^b   Watanabe, Y ^b   Bessho, A ^f   Eguchi, K ^f   Okimoto, N ^d   Harita, S ^e   Takemoto, M ^a   Hiraki, Y ^a   Harada, M ^a   Tanimoto, M ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Japanese Red Cross Okayama Hospital   (Japan)

^c Sumitomo Besshi Hospital   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e CHUGOKU CENTRAL HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Cisplatin; Combination chemotherapy; Concurrent chemoradiation; Docetaxel; Lung cancer

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEVER; GRANULOCYTOPENIA; HEALTH STATUS; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; ORGAN; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RESPIRATORY FAILURE; STOMATITIS; THORAX; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TAXOIDS;

EID: 0141841805     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601217     Document Type: Article

References (44)

1. Albain KS, Crowley JJ, Turrisi III AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Robert B, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathological stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II study, SWOG 9019. J Clin Oncol 20: 3454-3460
2. Alvarez MV, Cobreros G, Heras A, Lopez Zumel MC (1978) Studies on cis-dichloro diammineplatinum (II) as a radiosensitizer. Br J Cancer 37(Suppl): S68-S72
3. Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, Matsushita A, Kohara H, Harada M (1999) Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 19(1A): 291-299
4. Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, Pennington K, O'Connor T, Rynard S, Miller M, Einhorn L (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13: 1425-1429
5. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16: 3316-3322
6. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346
7. Creane M, Seymour CB, Colucci S, Mothersill C (1999) Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 75: 731-737
8. Curran WJ, Scott C, Langer C, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal S, Byhardt R, Sause W, Cox J (2000) Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19: 484 (Abstr)
9. Date H, Kiura K, Ueoka H, Tabata M, Aoe M, Andou A, Shibayama T, Shimizu N (2002) Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer 86: 530-533
10. Dewit L (1987) Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13: 403-426
11. Dillman RO, Herndon J, Seagren SL, Eaton Jr WL, Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215
12. Frasci G, Comella P, Scoppa G, Guida C, Gravina A, Fiore F, Casaretti R, Daponte A, Parziale A, Comella G (1997) Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study. J Clin Oncol 15: 1409-1417
13. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699
14. Giaccone G, Manegold C, Rosell R, Gatzemeier U, Quoix E (1998) An update on European randomized studies in non-small cell lung cancer. Semin Oncol 25(4 Suppl 9): 11-17
15. Gandara DR, Lara Jr PN, Goldberg Z, Lau DH (2001) Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: focus on docetaxel. Semin Oncol 28(Suppl 9): S26-S32
16. Greco FA, Stroup SL, Gray JR, Hainsworth JD (1996) Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 14: 1642-1648
17. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164-2168
18. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Nishiwaki Y, Ohashi A, Niitani H (2002) Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 296a (Abstr 1180)
19. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran Jr WJ (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 14(4): 1055-1064
20. Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non small cell lung cancer. A meta analysis. Cancer 76: 593-601
21. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3: 2431-2438
22. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18: 599-606
23. Matsushita A, Tabata M, Ueoka H, Kiura K, Shibayama T, Aoe K, Kohara H, Harada M (1999) Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Med Okayama 53: 67-75
24. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159-164
25. Milas L, Hunter NR, Mason KA, Abbruzzese JL (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55: 3564-3568
26. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L (2001) Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 7: 2887-2897
27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
28. Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M (1996) Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 35(2): 343-350
29. Robert F, Spencer SA, Childs III HA, Zhang R, Meredith RF, Wheeler RH, Hawkins MH, Carey D (2002) Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer 37(2): 189-199
30. Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, Fossella F, Kaukel E, Mattson K, Millward M, Kim YS, Gamza F, Berille J, Belani CP (2001) Multicenter, randomized phase III study of docetaxel+cisplatin (DC) and docetaxel+carboplatin (DCB) vs. vinorelbine+cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 20: 314a (Abstr 1252)
31. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13: 1539-1549
32. Sause W, Kolesar P, Taylor IV S, Johnson D, Livingston R, Komaki R, Emami B, Curran Jr W, Byhardt R, Dar AR, Turrisi III A (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364
33. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A (1992) Effects of concomitant cisplatin and radiotherapy on Inoperable non-small-cell lung cancer. N Engl J Med 326: 524-530
34. Segawa Y, Ueoka H, Kiura K, Tabata M, Takigawa N, Hiraki Y, Watanabe Y, Yonci T, Moritaka T, Hiyama J, Hiraki S, Tanimoto M, Hatada M (2003) Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer 41(1): 13-20
35. Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada M (2000) A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 82(1): 104-111
36. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103
37. Tishler RB, Geard CR, Hall EJ, Schiff PB (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497
38. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M, Klastersky (1994) Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467
39. Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S, Segawa Y, Harada M (1998) A randomized trial of hybrid administration of cyclophosphamide-adriamycin-vincristine (CAV)/cis-platin-etoposide versus sequential administration of CAV-PVP for the treatment of small-cell lung cancer: results of long term follow-up. Cancer 83: 283-290
40. Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Segawa Y, Chikamori K, Yonei T, Hiraki S, Harada M (1999) Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer 79(5/6): 984-990
41. Ueoka H, Tanimoto M, Kiura K, Tabata M, Takigawa N, Segawa Y, Takata I, Eguchi K, Okimoto N, Harita S, Kamei H, Shibayama T, Watanabe Y, Hiraki S, Harada M (2001) Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br J Cancer 85(1): 9-13
42. van Meerbeeck JP (2001) Staging of non-small cell lung cancer: consensus, controversies and challenges. Lung Cancer 34(Suppl 2): S95-S107
43. Wu HG, Bang YJ, Choi EK, Ahn YC, Kim YW, Lim TH, Suh C, Park K, Park CI (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52: 75-80
44. Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J (1998) Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16: 1948-1953